Month: November 2020

Month-end rebalancing, China tensions and the RBA

Month end has pushed the US dollar lower, then higher in the session overnight says NAB’s Ray Attrill. Meanwhile, no news on the EU recovery fund, OPEC or the UK-EU trade deal. Plus, should markets be worried about the tensions with China?

Gone Fishing

The month ends with big rises in equities driven by vaccine hopes, says NAB’s Rodrigo Catril. Also, the pound could rebound today on hopes that a Brexit deal is about to be reached.

Astra Zeneca re-run, Lane’s credit concerns

A soggy day on the markets says NAB’s David de Garis, but the continue rise in base metals points to the growth in China, whilst the rest of the world struggles with the virus.

Ask Steve: Keynesian v Post Keynesian; Austrian v Chicago Schools

The Austrian School v the Chicago School v Keynesian economics v Post-Keynesianism. The differences explained on today’s Debunking Economics podcast with @profstevekeen

Not much to be thankful for

FOMC minutes confirm they are looking at buying at longer end of curve. NAB’s Ray Attrill say that this will perhaps happen sooner than expected.

Trump relents, oil climbs and Dow hits new high

Trump is ready to give the keys to the White House. NAB’s Rodrigo Catril says the news has given the market some positivity, along with Janet Yellen set to become Treasury Secretary in the US, together with more vaccine hopes.

More positive vaccine news, but equities are cautious

More vaccine news today, this time from Astra Zeneca. NAB’s David de Garis says we’re seeing the return of hotels and airlines stocks at the expense of the tech sector, whilst the US dollar has been helped by better than expected Markit PMIs.

Revised Aussie Growth Forecast and a Fed-Treasury Spat

Australia’s 2021 growth forecast has been revised. NAB’s Tapas Strickland talks through the good news, plus the spat between the US Fed and the Treasury.

Lockdown jitters

The ferocity of the virus numbers of the US is seeing markets taking a more pessimistic short term view, despite positive vaccine news, says NAB’s Gavin Friend.

Lockdowns and infections overshadow further positive vaccine news

Pfizer is days away from submitted their vaccine for FDA approval. The markets haven’t been excited by the news. NAB’s David de Garis says rising COVID numbers have overshadowed the response.

Scroll to top